Dyne Therapeutics, Inc. – NASDAQ:DYN

Add to watchlist

$12.25

-11.46

-48.36%

Market closed

Open in 2 days

-42.90%

month

-42.90%

quarter

+73.90%

year

Market Cap	2.39B
Enterprise value	316.79M

P/E	-3.17
EV/Sales	N/A
EV/EBITDA	-1.93
Price/Sales	N/A
Price/Book	1.81
PEG ratio	0.30
EPS	-3.97

Revenue	N/A
EBITDA	-264.47M
Income	-257.39M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Dyne Therapeutics, Inc. (NASDAQ:DYN): Profit margin
Jun 2023	0	-64.90M
Sep 2023	0	-60.21M
Dec 2023	3.78M	-66.63M	-1759.19%
Mar 2024	0	-65.64M

Dyne Therapeutics Financials Estimate

Q Y

Dyne Therapeutics, Inc. (NASDAQ:DYN): Analyst Estimates
Mar 2024	0	-65.64M
Sep 2025	3.78M	-69.37M	-1831.43%
Oct 2025	0	-69.37M
Dec 2025	0	-72.77M

Analysts Price target
Financials & Ratios estimates

Dyne Therapeutics, Inc. (NASDAQ:DYN): Debt to assets
Jun 2023	251421000	44.54M	17.72%
Sep 2023	205244000	53.20M	25.92%
Dec 2023	165082000	73.79M	44.7%
Mar 2024	522279000	44.22M	8.47%

Dyne Therapeutics, Inc. (NASDAQ:DYN): Cash Flow
Jun 2023	-55.64M	17.23M	24.90M
Sep 2023	-50.60M	12.82M	454K
Dec 2023	-35.00M	26.19M	147K
Mar 2024	-78.53M	-179.83M	408.38M

Dyne Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Dyne Therapeutics, Inc. (NASDAQ:DYN): Employee count
Aug 2023	122
Sep 2023	134
Oct 2023	134
Nov 2023	134
Dec 2023	136
Jan 2024	136
Feb 2024	136
Mar 2024	141
Apr 2024	141
May 2024	141
Jun 2024	143
Jul 2024	143

Dyne Therapeutics
Hedge Funds Holdings Q1 2023

41.68% -54.93%

of DYN is owned by hedge funds

68 -46

hedge funds hold DYN stock

21.54M -28.38M

shares is hold by hedge funds

DYN hedge funds holdings changes

Dyne Therapeutics
Insider Trading

Dyne Therapeutics, Inc. (NASDAQ:DYN): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	1714285	435498
Feb 2024	0	1495731
Mar 2024	0	911239
May 2024	0	13186
Aug 2024	0	728625
Sep 2024	8000	388973
Oct 2024	0	80160
Nov 2024	0	42605
Dec 2024	0	385890

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	9 Dec 2024	KERSTEN DIRK director director	Common Stock	34,437	$29.18	$1,004,872
Sale	6 Dec 2024	KERSTEN DIRK director director	Common Stock	101,675	$29.34	$2,983,145
Sale	5 Dec 2024	KERSTEN DIRK director director	Common Stock	3,806	$29.05	$110,564
Sale	4 Dec 2024	KERSTEN DIRK director director	Common Stock	135,039	$29.39	$3,968,796
Sale	3 Dec 2024	KERSTEN DIRK director director	Common Stock	29,732	$29.05	$863,715
Sale	2 Dec 2024	KERSTEN DIRK director director	Common Stock	79,973	$29.66	$2,371,999
Sale	2 Dec 2024	KERSTEN DIRK director director	Common Stock	1,228	$30.37	$37,294
Option	18 Nov 2024	INCERTI CARLO director director	Stock option (right to buy)	16,500	$8.69	$143,385
Option	18 Nov 2024	INCERTI CARLO director director	Common Stock	16,500	$8.69	$143,385
Sale	18 Nov 2024	INCERTI CARLO director director	Common Stock	16,500	$28.73	$474,045

DYN insider trading transactions

Dyne Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q2 2017 4 Aug 2017	Q2 2017 Earnings Call Transcript
Q1 2017 6 May 2017	Q1 2017 Earnings Call Transcript
Q4 2016 24 Feb 2017	Q4 2016 Earnings Call Transcript
Q3 2016 6 Nov 2016	Q3 2016 Earnings Call Transcript

DYN earnings call transcripts

Dyne Therapeutics
Executives

Insider	Age	Compensation
Mr. Joshua T. Brumm (1978) Chief Executive Officer, Pres & Director	47	$789,440
Dr. Romesh Subramanian Ph.D. (1966) Co-Founder & Advisor	59	$565,170
Ms. Susanna Gatti High M.B.A. (1968) Chief Operating Officer	57	$409,310

Dyne Therapeutics
Latest News

Monday, 11 November 2024
18:15	Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases	seekingalpha.com
Thursday, 7 November 2024
16:15	Dyne Therapeutics to Present at Upcoming Investor Conferences	globenewswire.com
Monday, 4 November 2024
18:15	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations	accesswire.com
Sunday, 3 November 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
Saturday, 2 November 2024
11:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	prnewswire.com
11:00	The Schall Law Firm Encourages Investor Participation In A Case Against Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Thursday, 31 October 2024
22:30	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
Tuesday, 29 October 2024
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
Sunday, 27 October 2024
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Saturday, 26 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Contact The Schall Law Firm	accesswire.com
Friday, 25 October 2024
17:52	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	prnewswire.com
Wednesday, 23 October 2024
18:30	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
Monday, 21 October 2024
16:45	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Sunday, 20 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Impacted Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
Saturday, 19 October 2024
11:00	The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Friday, 18 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
Thursday, 17 October 2024
11:00	The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Related Infractions	accesswire.com
Tuesday, 15 October 2024
20:30	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Monday, 14 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Help The Schall Law Firm	accesswire.com
Sunday, 13 October 2024
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Saturday, 12 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
Friday, 11 October 2024
17:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	accesswire.com
11:00	The Schall Law Firm Encourages Investors To Join An Inquiry Into Dyne Therapeutics, Inc. For Securities Law Violations	accesswire.com
Thursday, 10 October 2024
11:00	Dyne Therapeutics Inc Is Being Investigated For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
Wednesday, 9 October 2024
17:41	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN	prnewswire.com

Ideas & Opinions

Seeking Alpha 18 Jun 2025

Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade
Seeking Alpha 10 Jan 2025

NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
Seeking Alpha 10 Sep 2023

Dyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early Stages
Seeking Alpha 28 May 2023

Dyne Therapeutics: FORCE Platform Poised To Revolutionize Gene Therapy
Seeking Alpha 9 Mar 2023

Avidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells
Seeking Alpha 19 Jan 2023

Diving Into Dyne Therapeutics

Frequently Asked Questions (FAQ)

What's the price of Dyne Therapeutics stock today?

One share of Dyne Therapeutics stock can currently be purchased for approximately $12.25.
When is Dyne Therapeutics's next earnings date?

Unfortunately, Dyne Therapeutics's (DYN) next earnings date is currently unknown.
Does Dyne Therapeutics pay dividends?

No, Dyne Therapeutics does not pay dividends.
How much money does Dyne Therapeutics make?

Dyne Therapeutics has a market capitalization of 2.39B.
What is Dyne Therapeutics's stock symbol?

Dyne Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DYN".
What is Dyne Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Dyne Therapeutics?

Shares of Dyne Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Dyne Therapeutics's key executives?
Dyne Therapeutics's management team includes the following people:
- Mr. Joshua T. Brumm Chief Executive Officer, Pres & Director(age: 47, pay: $789,440)
- Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor(age: 59, pay: $565,170)
- Ms. Susanna Gatti High M.B.A. Chief Operating Officer(age: 57, pay: $409,310)
Is Dyne Therapeutics founder-led company?

Yes, Dyne Therapeutics is a company led by its founder Dr. Romesh Subramanian Ph.D..
How many employees does Dyne Therapeutics have?

As Jul 2024, Dyne Therapeutics employs 143 workers, which is 1% more then previous quarter.
When Dyne Therapeutics went public?

Dyne Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 17 Sep 2020.
What is Dyne Therapeutics's official website?

The official website for Dyne Therapeutics is dyne-tx.com.
Where are Dyne Therapeutics's headquarters?

Dyne Therapeutics is headquartered at 1560 Trapelo Road, Waltham, MA.
How can i contact Dyne Therapeutics?

Dyne Therapeutics's mailing address is 1560 Trapelo Road, Waltham, MA and company can be reached via phone at +7 817868230.

Dyne Therapeutics, Inc.

dyne-tx.com

Exchange:

NASDAQ

Full time employees:

173

Industry:

Biotechnology

Sector:

Healthcare

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

+7 817868230

1560 Trapelo Road
Waltham, MA 02451

CIK: 0001818794
ISIN: US26818M1080
CUSIP: 26818M108